TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26433886

Group type: EXPERIMENTAL
Intervention: Hemodialysis patients with fistula
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Hemodialysis patients without fistula
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Hemodialysis patients (both groups)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Hemodialysis patients with fistulas
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Hemodialysis patients without fistulas
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Hemodialysis patients
Number of subjects: 38
Study: 23371471

Group type: EXPERIMENTAL
Intervention: Augmented feedback on jumping (AF)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (CTRL)
Number of subjects: 37
Study: 20965755

Group type: EXPERIMENTAL
Intervention: GTN (0.9 mg sublingual)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 28
Study: 19923521

Group type: EXPERIMENTAL
Intervention: 1.5 L crystalloid (Hartman's solution)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.5 L of 6% w/v hydroxyethyl starch (HES) solution (HES 0.5)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1 L of 6% w/v HES solution (HES 1.0)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 60
Study: 17199235

Group type: EXPERIMENTAL
Intervention: donepezil 5 mg/day
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: donepezil 10 mg/day
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: donepezil
Number of subjects: 579
Study: 15129975

Group type: EXPERIMENTAL
Intervention: Mini-matrix formulation F-1 (30% ibuprofen, 35% ethyl cellulose, 35% hydroxypropyl methylcellulose)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Mini-matrix formulation F-2 (60% ibuprofen, 20% ethyl cellulose, 20% xanthan gum)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Commercially available sustained release product (Ibu-slow)
Number of subjects: 9
Study: 11313163

Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg/day
Number of subjects: 10
Study: 9140209

Group type: EXPERIMENTAL
Intervention: Hot condition (89.6 degrees C)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Neutral condition (13.7 degrees C)
Number of subjects: 16
Study: 7943695

Group type: EXPERIMENTAL
Intervention: Sufentanil 5 micrograms
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sufentanil 7.5 micrograms
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sufentanil 10 micrograms
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (0.125% bupivacaine with adrenaline)
Number of subjects: 150
Study: 3282846

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily for four weeks
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily for eight weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily for four weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily for eight weeks
Number of subjects: 61
Study: 30738417

Group type: EXPERIMENTAL
Intervention: Hydraulic expansion
Number of subjects: 190

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 190
Study: 31192555

Group type: EXPERIMENTAL
Intervention: Oat porridge (70 grams daily for 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rice porridge (4 weeks)
Number of subjects: 0
Study: 27495344

Group type: COMPARATOR
Intervention: TAPP repair
Number of subjects: 160

Group type: COMPARATOR
Intervention: TEP repair
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Laparoscopic inguinal hernia repair (both TEP and TAPP)
Number of subjects: 160
Study: 25167799

Group type: COMPARATOR
Intervention: Standard triple therapy (PAC) - proton pump inhibitor with amoxicillin and clarithromycin twice a day for 7 days
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Pronase combined with standard triple therapy (PACE) - pronase (20,000 tyrosine units) with proton pump inhibitor, amoxicillin, and clarithromycin twice a day for 7 days
Number of subjects: 112
Study: 23219286

Group type: EXPERIMENTAL
Intervention: Continue tamoxifen to 10 years
Number of subjects: 6846
Study: 21715572

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/day, titrated to 100 mg/day after 6 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no losartan)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 32
Study: 18304285

Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: PCP education
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Both PCP and patient education
Number of subjects: 1029

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Education (general)
Number of subjects: 1029
Study: 16242256

Group type: EXPERIMENTAL
Intervention: 76 Gy in 38 fractions (Arm I)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 70.2 Gy in 26 fractions (Arm II)
Number of subjects: 100
Study: 12705512

Group type: EXPERIMENTAL
Intervention: 300 mg slow-release caffeine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30-min. nap
Number of subjects: 12
Study: 10905362

Group type: EXPERIMENTAL
Intervention: LAC 400 regimen (400 mg clarithromycin)
Number of subjects: 175

Group type: COMPARATOR
Intervention: LAC 800 regimen (800 mg clarithromycin)
Number of subjects: 175
Study: 8833461

Group type: COMPARATOR
Intervention: Positive control (skin irritant substance or product)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Negative control (compound with low irritant potential)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Chamber scarification test
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intra-individual variation
Number of subjects: 26
Study: 1418278

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lytic solution
Number of subjects: 60
Study: 3882611

Group type: EXPERIMENTAL
Intervention: Iohexol 240 mg I/ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iohexol 300 mg I/ml
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meglumine‐Ca metrizoate 200 mg I/ml
Number of subjects: 0
Study: 31929374

Group type: EXPERIMENTAL
Intervention: 800 mg IV ibuprofen administered every 6 hours for a total of 8 doses within 48 hours
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo administered every 6 hours for a total of 8 doses within 48 hours
Number of subjects: 99
Study: 30088971

Group type: EXPERIMENTAL
Intervention: Four Supports intervention (emotional support, communication support, decisional support, anticipatory grief support)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Four Supports intervention
Number of subjects: 300

Group type: COMPARATOR
Intervention: Education control
Number of subjects: 300
Study: 26250833

Group type: EXPERIMENTAL
Intervention: Ivacaftor 150 mg every 12 hours for 48 weeks
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 26276068

Group type: EXPERIMENTAL
Intervention: Hospital-based and telemonitoring guided home-based exercise training (CRT-Ex group) 5 times a week for 8 weeks.
Number of subjects: 52

Group type: COMPARATOR
Intervention: Hospital rehabilitation without a training program after discharge (CRT-Control group).
Number of subjects: 52
Study: 23218065

Group type: EXPERIMENTAL
Intervention: Positive handling (gentle handling with soft voices, slow movements, patting)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Negative handling (rough handling with rough voices, rapid movements, pushing)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Positive handling
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Negative handling
Number of subjects: 40
Study: 21349192

Group type: EXPERIMENTAL
Intervention: Chlorthalidone and amiloride
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 1200
Study: 19047545

Group type: EXPERIMENTAL
Intervention: Asthma questionnaire and lung function testing
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Percentages of predicted FEV(1) and predicted FEF(25%-75%) and FEV(1)/FVC
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Adding FEV(1)/FVC to symptom history
Number of subjects: 224
Study: 16571371

Group type: EXPERIMENTAL
Intervention: Placebo treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reduction of laser intensity
Number of subjects: 0
Study: 15137554

Group type: EXPERIMENTAL
Intervention: Extended stroke unit service (extended service)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Ordinary stroke unit service (ordinary service)
Number of subjects: 62
Study: 10769522

Group type: EXPERIMENTAL
Intervention: Ultrasound guided percutaneous drainage
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ultrasound guided percutaneous drainage for simple abscesses
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ultrasound guided percutaneous drainage for complex abscesses
Number of subjects: 26
Study: 9351734

Group type: EXPERIMENTAL
Intervention: Agreement approach using clinical and exercise test variables
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Three prediction equations (developed by the study and two others)
Number of subjects: 1080
Study: 8155409

Group type: EXPERIMENTAL
Intervention: Radiographic trabecular pattern observation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Menopausal status
Number of subjects: 0
Study: 2940499

Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29304083

Group type: EXPERIMENTAL
Intervention: Maternal STIs (CT, TP, NG, CMV)
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: Maternal CMV
Number of subjects: 899

Group type: EXPERIMENTAL
Intervention: Infant congenital CMV
Number of subjects: 899
Study: 26896559

Group type: EXPERIMENTAL
Intervention: Quadrupedal gait training programme
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 22
Study: 24999369

Group type: EXPERIMENTAL
Intervention: Avatar therapy (6 sessions of 30 minutes each)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard clinical care (control group)
Number of subjects: 0
Study: 22538186

Group type: EXPERIMENTAL
Intervention: High incentive with sadness prime
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Low incentive with sadness prime
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: High incentive with anger prime
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Low incentive with anger prime
Number of subjects: 62
Study: 20494464

Group type: EXPERIMENTAL
Intervention: Oral professional care with mucosal care
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral professional care without mucosal care
Number of subjects: 50
Study: 18831889

Group type: EXPERIMENTAL
Intervention: 2.5 mg 0.5% bupivacaine plus 25 microg fentanyl (group BF)
Number of subjects: 35

Group type: COMPARATOR
Intervention: 5 mg 0.5% bupivacaine alone (group B)
Number of subjects: 35
Study: 15882458

Group type: EXPERIMENTAL
Intervention: Electronic stethoscope
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional acoustic stethoscope
Number of subjects: 48
Study: 11708710

Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Concentric exercise
Number of subjects: 16
Study: 9223885

Group type: EXPERIMENTAL
Intervention: Low dose midazolam (MZ) administered i.v. at doses of 0, 0.03, 0.06 mg.kg‐1
Number of subjects: 70
Study: 8132916

Group type: EXPERIMENTAL
Intervention: Systematic clinical supervision combined with individualized care (Experimental Ward)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control Ward (no intervention)
Number of subjects: 38
Study: 2957057

Group type: EXPERIMENTAL
Intervention: Intracoronary thrombolysis followed by immediate coronary angioplasty
Number of subjects: 533

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Late patency of the infarct related vessel postthrombolytic therapy without angioplasty
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Combined procedure of thrombolysis and angioplasty (group B)
Number of subjects: 533
Study: 29424674

Group type: EXPERIMENTAL
Intervention: Lumbar corset usage
Number of subjects: 54

Group type: COMPARATOR
Intervention: No lumbar corset usage (Control)
Number of subjects: 54
Study: 26643541

Group type: EXPERIMENTAL
Intervention: NSI-189 40 mg q.d. (n=6)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NSI-189 40 mg b.i.d. (n=6)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NSI-189 40 mg t.i.d. (n=6)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (n=2)
Number of subjects: 24
Study: 23693155

Group type: EXPERIMENTAL
Intervention: Pharmacist-led smoking cessation intervention with at least three support sessions (during hospital stay, post-discharge, and within one month post-discharge) and free smoking cessation medications during hospital stay and for at least one week after discharge.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care provided by the hospital.
Number of subjects: 0
Study: 21300711

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 20025727

Group type: EXPERIMENTAL
Intervention: Home-based smoking prevention program 'Smoke-free Kids' consisting of five printed activity modules designed to improve parenting skills specific to smoking prevention and parent-child communication regarding smoking.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition with solely information on smoking and tobacco use.
Number of subjects: 0
Study: 17038074

Group type: EXPERIMENTAL
Intervention: Self-management program for AMD (n=12)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control conditions (n=20)
Number of subjects: 32
Study: 12782168

Group type: EXPERIMENTAL
Intervention: Contrast sensitivity tests using the Vistech contrast sensitivity test chart (VCTS 6500)
Number of subjects: 0
Study: 11860915

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9375336

Group type: EXPERIMENTAL
Intervention: Beta-blockade (100 mg atenolol) before training
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Beta-blockade (100 mg atenolol) after training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo-control before training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo-control after training
Number of subjects: 16
Study: 8298585

Group type: EXPERIMENTAL
Intervention: Single dose of 3 g fosfomycin trometamol
Number of subjects: 231

Group type: COMPARATOR
Intervention: Seven days of nitrofurantoin 50 mg four times daily
Number of subjects: 231
Study: 3236329

Group type: EXPERIMENTAL
Intervention: Torasemide 2.5 mg once daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29687553

Group type: EXPERIMENTAL
Intervention: Nomogram based on six variables (age, alpha fetoprotein, neutrophil-to-lymphocyte ratio, international normalized ratio, tumour size, tumour number)
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Nomogram model
Number of subjects: 1135
Study: 28473158

Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium histolyticum (CCH)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Percutaneous needle fasciotomy (PNF)
Number of subjects: 50
Study: 26191947

Group type: EXPERIMENTAL
Intervention: 30‐min SFAS session
Number of subjects: 97

Group type: COMPARATOR
Intervention: Education control session
Number of subjects: 97
Study: 24320900

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) combined with metronidazole (MTZ) + amoxicillin (AMX) for 14 days
Number of subjects: 30
Study: 21867369

Group type: EXPERIMENTAL
Intervention: Morning school schedule (07:30 - 12:00)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Afternoon school schedule (13:00 - 17:30)
Number of subjects: 379
Study: 19187664

Group type: EXPERIMENTAL
Intervention: Gentamycin
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 0.5% Povidone-iodine
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 5.0% Povidone-iodine
Number of subjects: 300

Group type: COMPARATOR
Intervention: All groups (Gentamycin, 0.5% Povidone-iodine, 5.0% Povidone-iodine)
Number of subjects: 300
Study: 21936254

Group type: EXPERIMENTAL
Intervention: Arthroscopically-assisted repair
Number of subjects: 44

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 44
Study: 16034556

Group type: EXPERIMENTAL
Intervention: 14-day contingent payment for smoking abstinence (14C)
Number of subjects: 63

Group type: COMPARATOR
Intervention: 7-day contingent payment for smoking abstinence (7C)
Number of subjects: 63

Group type: COMPARATOR
Intervention: 1-day contingent payment for smoking abstinence (1C)
Number of subjects: 63
Study: 12127203

Group type: EXPERIMENTAL
Intervention: Divalproex (DVPX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9772311

Group type: EXPERIMENTAL
Intervention: Avaxim
Number of subjects: 185

Group type: COMPARATOR
Intervention: Havrix
Number of subjects: 185
Study: 8027937

Group type: EXPERIMENTAL
Intervention: TempaDOT
Number of subjects: 502

Group type: COMPARATOR
Intervention: IVAC
Number of subjects: 502

Group type: COMPARATOR
Intervention: off-the-shelf glass
Number of subjects: 502
Study: 3140592

Group type: EXPERIMENTAL
Intervention: Dihydroergocristine (10 mg capsules, twice a day for 5 days, then 3 times a day for 5 days if treatment failed)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bromocriptine (2.5 mg capsules, twice a day for 5 days, then 3 times a day for 5 days if treatment failed)
Number of subjects: 30
Study: 30075534

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg and 10 mg BID
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study: 28583732

Group type: EXPERIMENTAL
Intervention: Topical Negative Pressure (TNP) therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (regular topical dressings)
Number of subjects: 22
Study: 26125448

Group type: EXPERIMENTAL
Intervention: Selumetinib (AZD6244, ARRY‐142886) + docetaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 0
Study: 23095760

Group type: EXPERIMENTAL
Intervention: Inappropriate left ventricular hypertrophy (LVM(inappr))
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: LVM(inappr)
Number of subjects: 626

Group type: COMPARATOR
Intervention: LVM or LVMI
Number of subjects: 626
Study: 20350029

Group type: EXPERIMENTAL
Intervention: unsupported online CCBT
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: CCBT&TAU
Number of subjects: 303

Group type: COMPARATOR
Intervention: CCBT, TAU, CCBT&TAU
Number of subjects: 303
Study: 18253905

Group type: EXPERIMENTAL
Intervention: Dextrose solution
Number of subjects: 174

Group type: COMPARATOR
Intervention: Sodium hyaluronate (SHA)
Number of subjects: 174
Study: 17175820

Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg every 8 hours)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg every 8 hours)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combined analgesic (50 mg tramadol every 8 hours and 200 mg ibuprofen every 8 hours)
Number of subjects: 45
Study: 15015908

Group type: EXPERIMENTAL
Intervention: Music therapy treatment (n=6, n=5)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Waitlist control group (n=4)
Number of subjects: 15
Study: 10971455

Group type: EXPERIMENTAL
Intervention: 1 mg of melatonin orally during oestradiol replacement
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo during oestradiol replacement
Number of subjects: 14
Study: 8839900

Group type: EXPERIMENTAL
Intervention: Fadrozole, 1 mg twice daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Tamoxifen, 20 mg daily
Number of subjects: 80
Study: 1531483

Group type: EXPERIMENTAL
Intervention: Fadrozole 4 mg daily for 14 days
Number of subjects: 8
Study: 6829674

Group type: EXPERIMENTAL
Intervention: 50 burns administered over one half the trabecular meshwork (Group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 100 burns administered over the entire trabecular meshwork (Group 2)
Number of subjects: 40
Study: 31321524

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sennosides
Number of subjects: 70
Study: 28917689

Group type: EXPERIMENTAL
Intervention: Early statin group (pitavastatin 4 mg/day from baseline)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Late statin group (pitavastatin 4 mg/day from 3 weeks after baseline)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Early statin group
Number of subjects: 53

Group type: COMPARATOR
Intervention: Late statin group
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study: 27264216

Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation Decision Support Tool (AFDST)
Number of subjects: 1493

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1493
Study: 25418492

Group type: EXPERIMENTAL
Intervention: High doses of Candesartan (32 mg)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Conventional doses of Candesartan (16 mg)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Antihypertensive treatment other than ARBs or angiotensin-converting enzyme inhibitors (Control group)
Number of subjects: 69
Study: 23020199

Group type: EXPERIMENTAL
Intervention: Incredible Years (IY) parent and child interventions for 6 months
Number of subjects: 49
Study: 21169164

Group type: EXPERIMENTAL
Intervention: Multimodal e-mental health intervention with manualized telephone support
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group not applicable (single arm trial)
Number of subjects: 21
Study: 19043945

Group type: EXPERIMENTAL
Intervention: Polymyxin B sulfate/trimethoprim, 1 drop four times daily for 7 days
Number of subjects: 56

Group type: COMPARATOR
Intervention: 0.5% Moxifloxacin, 1 drop three times daily for 7 days
Number of subjects: 56